Givosiran

Drug Profile

Givosiran

Alternative Names: ALN-AS1

Latest Information Update: 07 Jul 2017

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action 5 aminolevulinate synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute intermittent porphyria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute intermittent porphyria

Most Recent Events

  • 03 Jul 2017 Silence Therapeutics issues a claim in the UK High Courts of Justice (Patents Court) naming Alnylam UK Limited, Alnylam Pharmaceuticals and The Medicines Company UK Limited as defendants
  • 26 Jun 2017 Alnylam Pharmaceuticals plans to initiate phase III programme for givosiran in Acute intermittent porphyria in late 2017
  • 26 Jun 2017 Interim adverse events and efficacy data from a phase I trial in Acute intermittent porphyria released by Alnylam
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top